Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in Diabetic Macular Edema Patients Treated With Aflibercept (FORESIGHT)

NCT03780361 is registered in ClinicalTrials.gov with Hyewon Chung as lead sponsor.

NCT NCT03780361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03780361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in Diabetic Macular Edema Patients Treated With Aflibercept (FORESIGHT)
Lead sponsor
Hyewon Chung
Phase
Phase 4
Overall status
Completed
Start date
May 17, 2019
Completion date
February 1, 2024
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema